Ph.D. Noubar B. Afeyan

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D.
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Ph.D. Noubar B. Afeyan

Form 4 holding Director

Moderna, Inc.

Security class
Common Stock
Shares / value
3,880,328
Estimated value
$197,120,662
Report date
21 May 2026
Price
$50.80
Ownership
By Flagship Ventures Fund IV, L.P.
Form 4 holding Director

Moderna, Inc.

Security class
Common Stock
Shares / value
747,897
Estimated value
$37,993,167
Report date
21 May 2026
Price
$50.80
Ownership
By Flagship Ventures Fund IV-Rx, L.P.
Form 4 holding Director

Moderna, Inc.

Security class
Common Stock
Shares / value
3,924
Estimated value
$183,800
Report date
21 May 2026
Price
$46.84
Ownership
By Flagship Pioneering, LLC
Form 4 holding Director

Moderna, Inc.

Security class
Common Stock
Shares / value
3,924
Estimated value
$115,699
Report date
11 Dec 2025
Price
$29.48
Ownership
By Flagship Pioneering, Inc.
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Common Stock
Shares / value
25,016,458
Estimated value
Report date
26 Feb 2026
Price
Ownership
By Flagship VentureLabs VI, LLC
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Common Stock
Shares / value
15,264,724
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Fund VII, L.P.
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Common Stock
Shares / value
12,723,940
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Fund VI, L.P.
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Common Stock
Shares / value
4,340,252
Estimated value
Report date
02 Mar 2026
Price
Ownership
By FPN II, L.P.
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Common Stock
Shares / value
2,777,752
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Special Opportunities Fund II, L.P.
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Common Stock
Shares / value
1,562,500
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Pioneering Medicines 02, LLC
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Common Stock
Shares / value
987,491
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Nutritional Health LTP Fund, L.P.
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
29,561
Estimated value
Report date
26 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Rubius Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
25,000
Estimated value
Report date
12 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Omega Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
18,118
Estimated value
Report date
07 Jun 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Moderna, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
12,908
Estimated value
Report date
06 May 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Fund VII, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Fund VI, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Nutritional Health LTP Fund, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Fund VII, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Fund VI, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Special Opportunities Fund II, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By FPN II, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Fund VII, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By Flagship Pioneering Special Opportunities Fund II, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Generate Biomedicines, Inc.

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
02 Mar 2026
Price
Ownership
By FPN II, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Moderna, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
11 Dec 2025
Price
Ownership
By Flagship Pioneering, Inc.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Moderna, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
21 May 2026
Price
Ownership
By Flagship Pioneering, LLC
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Ph.D. Noubar B. Afeyan

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .